IL17A and breast carcinoma: Such evidence for a cross-talk between IL-17A and MMP-9 suggest that their simultaneously targeting can be highly beneficial for inhibiting tumor progression in various types of cancer, including breast cancer, gastric cancer, cervical cancer, hepatocellular carcinoma, and lung cancer [13, 29, 32, 36, 39].